Literature DB >> 23429015

Ophthalmic manifestations of herpes zoster virus in patients with multiple myeloma following bone marrow transplantation.

Alhossain A Khalafallah1, Miriam Woodgate, Kurien Koshy, Andrew Patrick.   

Abstract

We report three patients with ophthalmic herpes zoster (HZ) manifestations on the background diagnosis of multiple myeloma (MM). It seems that immunocompromised status has caused reactivation of the varicella zoster virus (VZV) producing a well-characterised neurological syndrome and subsequent postherpetic neuralgia in two patients. One patient experienced lymphocytic leptomeningitis resulting in unilateral optic neuritis. All patients received similar myeloma disease-specific treatment prior to HZ reactivation. All patients were treated with thalidomide and steroids, and they thereafter underwent autologous stem cell transplantation. Prior to HZ reactivation they received new immunomodulatory drugs in the form of thalidomide in addition to bortezomib (2 patients) and lenalidomide (1 patient). Immediate specific antiviral therapy was successfully applied with intravenous acyclovir for 10 days, followed by long-term oral famciclovir maintenance. Two patients progressed to have chronic HZ ophthalmicus and postherpetic neuralgia requiring ongoing antiviral therapy and neuroepileptic medications for the neuropathic pain.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23429015      PMCID: PMC3603998          DOI: 10.1136/bcr-2012-007625

Source DB:  PubMed          Journal:  BMJ Case Rep        ISSN: 1757-790X


  16 in total

Review 1.  Varicella-zoster virus eye disease.

Authors:  T J Liesegang
Journal:  Cornea       Date:  1999-09       Impact factor: 2.651

2.  Herpes zoster infection after autologous bone marrow transplantation.

Authors:  L M Schuchter; J R Wingard; S Piantadosi; W H Burns; G W Santos; R Saral
Journal:  Blood       Date:  1989-09       Impact factor: 22.113

Review 3.  Latest advances and current challenges in the treatment of multiple myeloma.

Authors:  Anuj Mahindra; Jacob Laubach; Noopur Raje; Nikhil Munshi; Paul G Richardson; Kenneth Anderson
Journal:  Nat Rev Clin Oncol       Date:  2012-02-21       Impact factor: 66.675

4.  Clinical stage-depending decrease of NK cell activity in multiple myeloma patients.

Authors:  Vladimir Jurisic; Tatjana Srdic; Gordana Konjevic; Olivera Markovic; Milica Colovic
Journal:  Med Oncol       Date:  2007       Impact factor: 3.064

Review 5.  Infections in patients with multiple myeloma in the era of high-dose therapy and novel agents.

Authors:  Marcio Nucci; Elias Anaissie
Journal:  Clin Infect Dis       Date:  2009-10-15       Impact factor: 9.079

6.  Bortezomib and the increased incidence of herpes zoster in patients with multiple myeloma.

Authors:  Seok Jin Kim; Kihyun Kim; Byung Soo Kim; Hyo-Jin Lee; Hawk Kim; Na-Ri Lee; Seung-Hyun Nam; Jung Hye Kwon; Hyo Jung Kim; Sang Kyun Sohn; Jong-Ho Won; Jae Hoon Lee; Cheolwon Suh; Sung-Soo Yoon; Hye Jin Kim; Inho Kim; Young-Rok Do; Won-Sik Lee; Young-Don Joo; Ho Jin Shin
Journal:  Clin Lymphoma Myeloma       Date:  2008-08

7.  Analysis of herpes zoster events among bortezomib-treated patients in the phase III APEX study.

Authors:  Asher Chanan-Khan; Pieter Sonneveld; Michael W Schuster; Edward A Stadtmauer; Thierry Facon; Jean-Luc Harousseau; Dina Ben-Yehuda; Sagar Lonial; Hartmut Goldschmidt; Donna Reece; Rachel Neuwirth; Kenneth C Anderson; Paul G Richardson
Journal:  J Clin Oncol       Date:  2008-08-18       Impact factor: 44.544

Review 8.  Herpes zoster ophthalmicus natural history, risk factors, clinical presentation, and morbidity.

Authors:  Thomas J Liesegang
Journal:  Ophthalmology       Date:  2008-02       Impact factor: 12.079

Review 9.  Bortezomib (PS-341): a novel, first-in-class proteasome inhibitor for the treatment of multiple myeloma and other cancers.

Authors:  Paul G Richardson; Teru Hideshima; Kenneth C Anderson
Journal:  Cancer Control       Date:  2003 Sep-Oct       Impact factor: 3.302

10.  Effect of immunoglobulin therapy on the rate of infections in multiple myeloma patients undergoing autologous stem cell transplantation or treated with immunomodulatory agents.

Authors:  Alhossain Khalafallah; Matthias Maiwald; Amanda Cox; Denise Burns; Gerald Bates; Terry Hannan; David Seaton; Bernadene Fernandopulle; Damien Meagher; Terry Brain
Journal:  Mediterr J Hematol Infect Dis       Date:  2010-04-20       Impact factor: 2.576

View more
  4 in total

1.  Expression and correlation of IL-2, IL-10 and TNF-α in patients with multiple myeloma-infected herpes zoster treated by bortezomib-containing regimen.

Authors:  Kang Liu; Yafei Yin; Xinfu Zhou; Kaibo Zhu; Zimian Luo
Journal:  Am J Transl Res       Date:  2021-12-15       Impact factor: 4.060

2.  Bortezomib-induced unfolded protein response increases oncolytic HSV-1 replication resulting in synergistic antitumor effects.

Authors:  Ji Young Yoo; Brian S Hurwitz; Chelsea Bolyard; Jun-Ge Yu; Jianying Zhang; Karuppaiyah Selvendiran; Kellie S Rath; Shun He; Zachary Bailey; David Eaves; Timothy P Cripe; Deborah S Parris; Michael A Caligiuri; Jianhua Yu; Matthew Old; Balveen Kaur
Journal:  Clin Cancer Res       Date:  2014-05-09       Impact factor: 12.531

Review 3.  Looking back to move forward: a twenty-year audit of herpes zoster in Asia-Pacific.

Authors:  Liang-Kung Chen; Hidenori Arai; Liang-Yu Chen; Ming-Yueh Chou; Samsuridjal Djauzi; Birong Dong; Taro Kojima; Ki Tae Kwon; Hoe Nam Leong; Edward M F Leung; Chih-Kuang Liang; Xiaohong Liu; Dilip Mathai; Jiun Yit Pan; Li-Ning Peng; Eduardo Rommel S Poblete; Philip J H Poi; Stewart Reid; Terapong Tantawichien; Chang Won Won
Journal:  BMC Infect Dis       Date:  2017-03-15       Impact factor: 3.090

4.  Ophthalmic herpes zoster with severe complications in an immunocompromised patient: A case report and review of the literature.

Authors:  Gabriela Mariana Iancu; Dan Mircea Stănilă; Remus Călin Cipăian; Maria Rotaru
Journal:  Exp Ther Med       Date:  2022-01-11       Impact factor: 2.447

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.